Abstract 1250P
Background
We conducted a retrospective analysis to evaluate the volume of the lungs and determine the presence of infiltration and consolidation. To accurately interpret anisotropies and voxel spacings and to maintain resilience even when dealing with unbalanced class distributions, we used nnU-Net with quantitative and qualitative assessments to detect Lung infiltration. Utilizing TCGA-LUAD data (Lung Adenocarcinoma) and TCGA-LUSC (Lung Squamous cell carcinoma) this retrospective study on segmentation for volumetric and consolidation assessments are conducted. Chest OMX is a diagnostic tool that can assess lung volume, which in turn enables various applications such as monitoring recurrence from the changes in Lung volume; identifying infiltration and response to the treatment from Lung Volume and lobes, and detecting abnormalities in the lung from Consolidation. By providing quantitative score values, it assists in tracking changes over time and facilitating decision-making in clinical diagnosis.
Methods
We used nnU-Net, a popular deep-learning framework designed for medical image segmentation tasks. By analyzing the volume, infiltration, and consolidation characteristics of a lung carcinoma on CT scans, we can assess the tumor's behavior and response to treatment. From regional lung segmentation invasion, the burden is calculated. Additionally, measurements of discovered lung lesions and dedication to the relevant lung lobe are performed, along with fully automated lung lobe segmentation. Lobe 3D uses a deep learning system to measure the volume of the five lobes of the lung. HAA is also analyzed towards the end. Patient cases are selected irrespective of their ages from the TCGA cohort group. The primary outcome was the assessment of lung volume and the extent of the infiltration.
Results
Table: 1250P
Chest OMX: Generated diagnosis report for the case TCGA-LUSC
Left lung (LL) cm3 | 1429.50 |
Right lung (RL) cm3 | 1516.38 |
Left upper lobe (LUL) cm3 | 807.24 |
Left lower lobe (LLL) cm3 | 603.17 |
Right upper lobe (RUL) cm3 | 618.34 |
Right middle lobe (RML) cm3 | 276.84 |
Right lower lobe (RLL) cm3 | 611.89 |
Left upper lobe (HAA) cm3 | 170.16 |
Left lower lobe (HAA) cm3 | 378.00 |
Right upper lobe (HAA) cm3 | 128.18 |
Right middle lobe (HAA) cm3 | 59.05 |
Right lower lobe (HAA) cm3 | 394.12 |
Volume (LUL, LLL, RUL, RML, RLL) cm3 | (807.24, 603.17, 618.34, 276.84, 611.89) |
Involvement (LUL, LLL, RUL, RML, RLL) cm3 | (378.00, 128.18, 59.05, 394.12) |
Infiltration percentage (LUL, LLL, RUL, RML, RLL) % | (21.08, 62.67, 20.73, 21.33, 64.41) |
Conclusions
The diagnostic tool, Chest OMX can analyze the lung tissue from CT scans to determine the volume, consolidation and extent of infiltration by cancerous cells.
Clinical trial identification
Editorial acknowledgement
The dataset acknowledgment for,
1.Albertina, B., Watson, M., Holback, C., Jarosz, R., Kirk, S., Lee, Y., Rieger-Christ, K., & Lemmerman, J. (2016). The Cancer Genome Atlas Lung Adenocarcinoma Collection (TCGA-LUAD) (Version 4) [Data set]. The Cancer Imaging Archive. https://doi.org/10.7937/K9/TCIA.2016.JGNIHEP5.[Data Citation]
2. Clark, K., Vendt, B., Smith, K., Freymann, J., Kirby, J., Koppel, P., Moore, S., Phillips, S., Maffitt, D., Pringle, M., Tarbox, L., & Prior, F. (2013). The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository. In Journal of Digital Imaging (Vol. 26, Issue 6, pp. 1045–1057). Springer Science and Business Media LLC. \https://doi.org/10.1007/s10278-013-9622-7.[TCIA Citation]
3.Kirk, S., Lee, Y., Kumar, P., Filippini, J., Albertina, B., Watson, M., Rieger-Christ, K., & Lemmerman, J. (2016). The Cancer Genome Atlas Lung Squamous Cell Carcinoma Collection (TCGA-LUSC) (Version 4) [Data set]. The Cancer Imaging Archive. \https://doi.org/10.7937/K9/TCIA.2016.TYGKKFMQ.[Data Citation]
Legal entity responsible for the study
PMX.Inc., USA and PMX, South Korea.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1774P - PC-PEP, a comprehensive daily six-month home-based prostate cancer: Patient empowerment program improves quality of life, physical fitness, and urinary function outcomes among prostate cancer patients with localized disease - Secondary analyses of a randomized clinical trial
Presenter: Gabriela Ilie
Session: Poster session 14
1775P - A newly-developed deep-learning algorithm: NAFNet outperforms ResNet50 for predicting adverse pathology events and biochemical recurrence time using MRI from prostate cancer patients
Presenter: Zheng Liu
Session: Poster session 14
1776P - Body composition in adult life and prostate cancer (PCa) incidence and mortality: The PROCA-life study
Presenter: Martin Støyten
Session: Poster session 14
1777P - Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints
Presenter: Ugo De Giorgi
Session: Poster session 14
1778P - Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
Presenter: Stephen Freedland
Session: Poster session 14
1779P - PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial
Presenter: Giulio Francolini
Session: Poster session 14
1780P - The health inequality impact of darolutamide for non-metastatic castration-resistant prostate cancer: A distributional cost-effectiveness analysis
Presenter: Jeroen Jansen
Session: Poster session 14
1782P - Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1|RT comparison
Presenter: Craig Jones
Session: Poster session 14
1783P - PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14